Slesak B, Harlozinska A, Porebska I, Bojarowski T, Lapinska J, Rzeszutko M, Wojnar A
Department of Tumor Immunology, Wroclaw University of Medicine, Poland.
Anticancer Res. 1998 Jul-Aug;18(4A):2727-32.
The expression and coexpression of EGFR, c-erbB-2 and c-erbB-3 in 21 gastric cancers and 20 chronic gastritis was examined using immunohistochemistry on fresh frozen tissues considering clinicopathological variables. Generally, gastric cancer patients showed a higher incidence of EGFR, c-erbB-2 and d-erbB-3 overexpression than the group with chronic gastritis (81% and 43%; 38% and 45%; 35% and 20%, respectively), however, statistically significant differences were found only for EGFR expression (p = 0.01). No association between immunoreactivity of all growth factor receptors and the histopathological structure of gastric cancer was observed. EGFR and c-erbB-3 proteins were detected more frequently in patients with III/IV than in I/II of TNM stages, while c-erbB-2 overexpression was higher in I/II vs. III/IV stages. In chronic gastritis with intestinal metaplasia and or coexisting carcinoma lesions, a higher frequency of the expression of studied proteins was observed in comparison with chronic gastritis without those alternations; however, these differences were statistically insignificant. The percentage of positive cases with coexpression of two proteins was comparable in gastric cancer and chronic gastritis (33% and 35%) but the simultaneous expression of all three receptors was evident only in gastric cancer (19%). Our results indicate that at least one or two members of EGFR related receptors could appear in the early stages of gastric tumorigenesis. The enhancement of c-erbB-2 and c-erbB-3 reactivity seems to cooperate with EGFR activation in the gastric cancer development. Our results indicate the promotional rather than direct transformational role for EGFR supergene family in gastric carcinogenesis.
利用免疫组织化学方法,在新鲜冷冻组织上,结合临床病理变量,检测了21例胃癌和20例慢性胃炎中表皮生长因子受体(EGFR)、原癌基因蛋白(c-erbB-2)和原癌基因蛋白(c-erbB-3)的表达及共表达情况。总体而言,胃癌患者中EGFR、c-erbB-2和c-erbB-3过表达的发生率高于慢性胃炎组(分别为81%和43%;38%和45%;35%和20%),然而,仅EGFR表达存在统计学显著差异(p = 0.01)。未观察到所有生长因子受体的免疫反应性与胃癌组织病理学结构之间存在关联。在TNM分期为III/IV期的患者中,EGFR和c-erbB-3蛋白的检测频率高于I/II期患者,而c-erbB-2过表达在I/II期高于III/IV期。与无这些改变的慢性胃炎相比,在伴有肠化生和/或共存癌病变的慢性胃炎中,所研究蛋白的表达频率更高;然而,这些差异无统计学意义。胃癌和慢性胃炎中两种蛋白共表达的阳性病例百分比相当(33%和35%),但仅在胃癌中出现了所有三种受体的同时表达(19%)。我们的结果表明,EGFR相关受体的至少一个或两个成员可能出现在胃癌发生的早期阶段。c-erbB-2和c-erbB-3反应性的增强似乎在胃癌发展过程中与EGFR激活协同作用。我们的结果表明,EGFR超基因家族在胃癌发生中起促进作用而非直接转化作用。